- Home
- LSTA vs ATOS Comparison
LSTA vs ATOS Comparison
Compare LSTA & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | ATOS |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 24.1M |
| IPO Year | 2000 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LSTA | ATOS |
|---|---|---|
| Price | $1.54 | $2.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $15.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 551.1K | 51.1K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,283,868.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $0.99 | $0.53 |
| 52 Week High | $5.07 | $7.56 |
Technical Indicators
Market Signals| Indicator | LSTA | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 47.80 |
| Support Level | $1.23 | $2.32 |
| Resistance Level | $2.11 | $2.60 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 42.61 | 37.34 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.